Nav: Home

The importance of the glutamine metabolism in colon cancer

January 10, 2017

The importance of glutamine metabolism for colon cancer was revealed by Masamitsu Konno, Ph.D, Masaaki Miyo, M.D. Ph.D, Masaki Mori, M.D. Ph.D and Hideshi Ishii, M.D. Ph.D. The aim of this study is to elucidate metabolic adaptation to nutritional stress and the role of the involved oncogenes in human colorectal cancer. The present study showed that the metabolism of colorectal cancer, distinct from that of pancreatic cancer, depended on genomic alterations, which previously have been uncharacterized, and was not restricted to KRAS mutation alone. Colorectal cancer can survive under the condition of glucose depletion while retaining TCA cycle activity. The cells' survival relies on a delicate balance between energy and reactive oxygen species (ROS) production. Glutamate dehydrogenase 1 (GLUD1) and SLC25A13 have pivotal roles under glucose-deprived conditions and are associated with tumor aggressiveness and colorectal cancer prognosis.

GLUD1 and SLC25A13 have pivotal roles in nutritional stress and are associated with tumor aggressiveness and poorer prognosis of colorectal cancer. These proteins may serve as new targets in the treatment of refractory colorectal cancer.

"We found that colorectal cancer cells survived under the condition of glucose depletion, and their resistance to such conditions depended on genomic alterations rather than on KRAS mutation alone. Metabolomic analysis demonstrated that those cells maintained TCA cycle activity and ATP production under such conditions. Furthermore, we identified pivotal roles of GLUD1 and SLC25A13 in nutritional stress. GLUD1 and SLC25A13 were associated with tumor aggressiveness and poorer prognosis of colorectal cancer. ", says Hideshi Ishii. "GLUD1 and SLC25A13 may serve as new targets in treating refractory colorectal cancer, which survives in malnutritional microenvironments."
-end-


Osaka University

Related Colorectal Cancer Articles:

New method for early screening of colorectal cancer
A highly sensitive method that can detect even the earlier stages of colorectal cancer has been developed by researchers in Japan.
Adults with disabilities screened less often for colorectal cancer
Colorectal cancer is the fourth most common type of cancer in the United States, with nearly 135,000 cases reported in 2016.
Colorectal cancer statistics, 2017
Despite dramatic reductions in overall colorectal cancer incidence and mortality, striking disparities by age, race, and tumor subsite remain
Gene mutations among young patients with colorectal cancer
While many patients with colorectal are diagnosed when they are older than 50, about 10 percent of patients are diagnosed at younger ages.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
New immunotherapy study at Sanford centers on colorectal cancer
Sanford Health has opened another clinical trial exploring the power of the body's immune system to fight cancer.
UA Cancer Center team questions safety, efficacy of selenium and colorectal cancer risk
Selenium has been a popular nutritional supplement for decades, touted for its antioxidant properties and its role in stopping free radicals from damaging cells and DNA.
How mouth microbes may worsen colorectal cancer
Bacteria commonly found in the mouth have been recently shown to worsen colorectal cancer in animals, but it has not been clear how these microbes make their way to the gut in the first place.
Pretargeted radioimmunotherapy may eliminate colorectal cancer
An emerging cancer therapy has colorectal tumors surrounded. Presenters at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging are unveiling a novel radioimmunotherapy that combines a cancer-seeking antibody with potent radionuclide agents, resulting in complete remission of colorectal cancer in mouse models.
As colorectal cancer rate falls, diagnosis of late-stage cancer in young patients is up
University of Colorado Cancer Center study presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2016 finds that in patients over 50, the rate of CRC is falling at 2.5 percent per year while the rate of CRC in patients under 50 is rising at 0.8 percent per year.

Related Colorectal Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Climate Crisis
There's no greater threat to humanity than climate change. What can we do to stop the worst consequences? This hour, TED speakers explore how we can save our planet and whether we can do it in time. Guests include climate activist Greta Thunberg, chemical engineer Jennifer Wilcox, research scientist Sean Davis, food innovator Bruce Friedrich, and psychologist Per Espen Stoknes.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...